Mitogenic Signals Initiated via Interleukin-6 Receptor Complexes in Cooperation with Other Transmembrane Molecules in Myelomas

スポンサーリンク

概要

• 論文の詳細を見る

• Cytokines exert multiple biological functions through binding to their specific receptors that triggers activation of intracellular signaling cascades. The cytokine-mediated signals may produce variable and even opposing effects on different cell types, depending on cellular context that is also dictated by the differentiation stage of the cell. Multiple myeloma (MM) is a monoclonal proliferative disorder of human plasma cells. Myeloma cells appear to include mixed subpopulations in accordance with the expression of their surface antigens, such as CD45. Although interleukin-6 (IL-6) is widely accepted as the most relevant growth factor for myeloma cells, only a few subpopulations of tumor cells, such as CD45+ immature cells, proliferate in response to IL-6. The activation of both signal transducer and activator of transcription (STAT) 3 and extracellular signal-regulated kinase (ERK) 1/2 is not sufficient for IL-6-induced proliferation of myeloma cells that requires the src family kinase activation associated with a rapid translocation of CD45 to lipid rafts. The CD45 expression renders myeloma cells competent for not only mitogenic but also apoptotic stimuli, resulting in either proliferation or apoptosis of CD45+ myeloma cells dependently upon the circumstantial stimuli. In contrast, in CD45- myeloma cells highly expressing IL-6 receptor α chain (IL-6Rα), IL-6Rα and insulin-like growth factor (IGF)-I receptors exist on plasma membrane in close proximity, facilitating efficient assembly of two receptors in response to IL-6. The synergistic effects of IL-6Rα on IGF-I receptor-mediated signals provide a novel insight into a Jak-independent IL-6 signaling mechanism of receptor cross talk in human myeloma cells. Furthermore, the signaling cross talk between the cytokine receptor, IL-6Rα/gp130 and the growth factor receptor tyrosine kinase, fibroblast growth factor receptor (FGFR) 3 appears in myeloma cells carrying t(4;14)(p16.3;q32). In this review we propose several mechanisms of the IL-6-induced cell proliferation that is strictly dependent upon the cellular context in myelomas. [J Clin Exp Hematopathol 46(2) : 55-66, 2006]

• 日本リンパ網内系学会の論文
• 2006-11-01

著者

• Kawano Michio

  Department Of Bio-signal Analysis Applied Medical Engineering Science Graduate School Of Medicine Ya

• Ishikawa Hideaki

  Department Of Bio-signal Analysis Applied Medical Engineering Science Graduate School Of Medicine Ya

• Tsuyama Naohiro

  Department Of Bio-signal Analysis Applied Medical Engineering Science Graduate School Of Medicine Ya

• Obata Masanori

  Department Of Bio-signal Analysis Applied Medical Engineering Science Graduate School Of Medicine Ya

• Ishikawa Hideaki

  Department Of Bio-signal Analysis Applied Medical Engineering Science Graduate School Of Medicine Ya

関連論文

• An Increase in MPC-1^- and MPC-1^-CD45^+ Immature Myeloma Cells in the Progressive States of Bone Marrow Plasmacytosis : The Revised Phenotypic Classification of Monoclonal Marrow Plasmacytosis (MOMP-2005)
• Involvement of CD8^+RT1.B^+ and CD4^+RT1.B^+ Cells of Cervical Lymph Nodes in the Immune Response After Corneal Transplantation in the Rat
• IMPROVED TRANSFECTION EFFICIENCY OF 3Y1 AND ITS DERIVATIVE CELLS
• Fracture of the distal end of the fibula through a persistent physis in an adult with fracture of the medial malleolus
• A new phenotypic classification of bone marrow plasmacytosis
• Biological significance of heterogeneity in human myeloma cells
• Mitogenic Signals Initiated via Interleukin-6 Receptor Complexes in Cooperation with Other Transmembrane Molecules in Myelomas
• Interleukin-6-Induced Proliferation of Human Myeloma Cells Associated with CD45 Molecules
• Interleukin 6 (BSF2/IL-6) is an Autocrine Growth Factor for Human Multiple Myelomas

スポンサーリンク